Brief: Landos Biopharma Announces Positive Results From A Phase 1 Study Of NX-13 In Healthy Volunteers04/03/2021 12:07
Brief: Landos Biopharma Inc Shares Open About 18.8% Below IPO Price In Debut On Nasdaq04/02/2021 17:32
Brief: Landos Biopharma Announces Pricing Of Initial Public Offering 6,250,000 Shares Of Common Stock At $16 Per Share04/02/2021 01:57
Last trade - 00:00Last trade - 00:00Last trade - 00:00